Please assess the completion status of the following clinical trial:

Trial Title: Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese men and women aged 20 years or older,~* Patients diagnosed as having Neovascular glaucoma (NVG) with neovascularization in the anterior segment (both iris and anterior chamber angle),~* Patients with Intraocular pressure (IOP) higher than 25 mmHg in the study eye due to anterior segment (both iris and anterior chamber angle) neovascularization.~Exclusion Criteria:~* Patients with angle-closure due to conditions other than Neovascular glaucoma~* Patients with a known or suspected ocular or peri-ocular infection,~* Patients with severe intraocular inflammation in the study eye,~* Women who are pregnant, suspected of being pregnant or lactating,~* Patients with known allergy to aflibercept.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aflibercept (Type: EXPERIMENTAL): Aflibercept 2 mg Intravitreal (IVT) injection group
- Sham Injection (Type: SHAM_COMPARATOR): Sham injection group

Based on this trial design, predict the completion outcome and termination type (if applicable).